周五盘前，美股上市公司脑再生科技（RGC）股价大跌13.20%，引发市场广泛关注。这家专注于研究中药治疗多动症和自闭症的小型药企，近期因涉及脑机接口技术而股价飙升，市值一度突破2800亿元人民币。
据悉，脑再生科技此前因一则未经证实的消息而引发股价暴涨。5月9日，市场传闻该公司新一代神经调控芯片通过FDA临床试验审批，并将与梅奥诊所合作开展帕金森病治疗研究。然而，公司并未在官方渠道证实这一消息。值得注意的是，公司近年来的研发投入规模有限且呈下降趋势，与高端芯片技术突破的说法难以匹配。
分析人士指出，脑再生科技股价的暴跌可能意味着投资者开始质疑公司的真实技术实力和市场估值。这一事件再次警示投资者，在新兴科技领域，需要谨慎区分真实的技术突破和市场炒作，避免陷入投机泡沫。随着市场逐渐回归理性，预计该股后市可能面临进一步调整。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.